{
  "docId": "019de075-4071-7657-953a-43c246cbe714",
  "docSlug": "684835678957e07d55af9fc01c6da54e",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 44 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 44,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "The slide uses a two-column layout to contrast pipeline scale with specific recent trial successes.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-4071-7657-953a-43c246cbe714/8",
  "deckHref": "/decks/019de075-4071-7657-953a-43c246cbe714",
  "deckJsonHref": "/decks/019de075-4071-7657-953a-43c246cbe714.json",
  "deckAnchorHref": "/decks/019de075-4071-7657-953a-43c246cbe714#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.45,
        "x": 0.03,
        "y": 0.76
      },
      "kind": "callout",
      "text": "10 potential blockbuster opportunities from 30 potential Phase III trials planned in 2023",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "61f11103-b90d-4e30-a3f0-e2bb4b2bf6d3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.45,
        "x": 0.52,
        "y": 0.4
      },
      "kind": "list",
      "text": "Tagrisso ADAURA OS (Adj EGFRm NSCLC)\nImfinzi AEGEAN (Neoadj-adj NSCLC)\nEnhertu DESTINY-Pantumor02 (HER2 expressing tumours)\nLynparza + Imfinzi + anti-VEGF + CTx DUO-O (ovarian)\nTagrisso + CTx FLAURA2 (EGFRm NSCLC)\nLynparza + Imfinzi + CTx DUO-E (endometrial)\nImfinzi + FLOT MATTERHORN (Neoadj-adj gastric and GEJ)\nDato-DxD TROPION-Lung01 (NSCLC)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "18a1e89d-2ffe-4bae-8d6c-fe2395e2e144",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.15,
        "x": 0.05,
        "y": 0.58
      },
      "kind": "metric",
      "text": "14",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "23414d28-dc25-4558-a77b-03be0aae5db5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.15,
        "x": 0.05,
        "y": 0.42
      },
      "kind": "metric",
      "text": ">120",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4f7924cc-be8e-4513-976d-e7026281929c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.25,
        "x": 0.18,
        "y": 0.42
      },
      "kind": "paragraph",
      "text": "ongoing late-stage clinical trials across our pipeline",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7571261e-c8a0-4fc4-8a60-ced2428db80a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.25,
        "x": 0.18,
        "y": 0.58
      },
      "kind": "paragraph",
      "text": "unique NMEs in late-stage development",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "826fb832-77e0-4df7-b9a5-4d0d4463e270",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.03,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "Phase III trial start defined as first patient clinically dosed. R&D = Research & Development; siRNA = small interfering ribonucleic acid; NME = new molecular entity; OS = overall survival; EGFRm = epidermal growth factor receptor mutant; NSCLC = non-small cell lung cancer; Neoadj-adj = neoadjuvant-adjuvant; HER2 = human epidermal growth factor receptor 2; anti-VEGF = anti-vascular endothelial growth factor; CTx = chemotherapy; FLOT = fluorouracil, leucovorin, oxaliplatin and docetaxel; GEJ = gastroesophageal junction.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f134ac13-5291-4f40-9f7f-524e6b6dd240",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.85,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "Leading late-stage pipeline, proven R&D execution",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6d7538be-48bc-4c7b-b9b9-c9848c3524d7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 8,
      "from": 5,
      "beatId": "30933710-1a3c-4b11-8c34-5237ef4835bc",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Need",
      "beatSlug": "monroes-sequence-need",
      "evidence": "The presentation highlights the demand for AstraZeneca's medicines and the need for innovative solutions",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 22,
      "from": 5,
      "name": "Pattern Hunter",
      "slug": "02-pattern-hunter",
      "bestFor": "Time-pressed audiences, building consensus, when data is strong",
      "matchId": "8f711e18-1f16-4fa6-b2d7-b917fe429d2f",
      "evidence": "The presentation highlights multiple examples of AstraZeneca's growth and innovation across different disease areas",
      "position": 0,
      "objective": "To identify patterns and trends in AstraZeneca's growth and innovation",
      "structure": "Evidence A -> Evidence B -> Evidence C -> Pattern/Conclusion",
      "confidence": 0.6,
      "description": "Group multiple pieces of evidence that together point to a pattern or conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}